Amedisys Inc (NASDAQ:AMED) was the target of unusually large options trading activity on Monday. Investors acquired 2,242 put options on the stock. This represents an increase of approximately 1,679% compared to the typical volume of 126 put options.
Several equities research analysts have recently weighed in on the stock. Craig Hallum downgraded shares of Amedisys from a “buy” rating to a “hold” rating and decreased their target price for the stock from $116.00 to $104.00 in a research note on Friday. SunTrust Banks increased their target price on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Cantor Fitzgerald increased their target price on shares of Amedisys from $117.00 to $125.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. ValuEngine upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Finally, Canaccord Genuity assumed coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $97.08.
Shares of NASDAQ:AMED opened at $100.89 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.21 and a quick ratio of 1.21. The stock has a market capitalization of $3.13 billion, a P/E ratio of 45.65, a PEG ratio of 1.50 and a beta of 1.00. Amedisys has a 52 week low of $45.60 and a 52 week high of $127.38.
In other news, insider David B. Pearce sold 398 shares of the stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares in the company, valued at $1,438,368.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Glenmede Trust Co. NA lifted its position in Amedisys by 4.3% in the second quarter. Glenmede Trust Co. NA now owns 71,559 shares of the health services provider’s stock valued at $6,116,000 after purchasing an additional 2,959 shares during the period. Moneta Group Investment Advisors LLC acquired a new stake in Amedisys in the second quarter valued at about $181,000. Algert Global LLC acquired a new stake in Amedisys in the second quarter valued at about $1,208,000. Cubist Systematic Strategies LLC lifted its position in Amedisys by 1,086.0% in the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after purchasing an additional 2,172 shares during the period. Finally, Piedmont Investment Advisors LLC increased its holdings in Amedisys by 9.3% in the second quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after buying an additional 567 shares in the last quarter. Hedge funds and other institutional investors own 93.19% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.